Allocca M, Fiorino G, Zallot C, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol. 2020;18:2134-2135.
Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatologic Treatment. 2020;31:317-318.
Ben-Horin S, Leszczyszyn J, Dudkowiak R, et al. OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis. J Crohn's Colitis. 2020;14:S021-S022.
British Society of Gastroenterology website. BSG expanded consensus advice for the management of IBD during the COVID-19 pandemic. Updated April 6, 2020. Accessed Aug 4, 2020. https://www.bsg.org.uk/covid-19-advice/bsg-advice-for-management-of-inflammatory-bowel-diseases-during-the-covid-19-pandemic/
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020. doi: 10.1016/j.cytogfr.2020.06.001. [Epub ahead of print]
COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27-38.
Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatologic Ther. 2020. doi: 10.1111/dth.13475. [Epub ahead of print]
Din S, Kent A, Pollok RC, et al. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. GUT. 2020. doi: 10.1136/gutjnl-2020-321927. [Epub ahead of print]
Ferrante M. Current use of fecal calprotectin in the management of patients with inflammatory bowel disease. Gastroenterol Hepatol. 2020;16:89-91.
Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol. 2020. doi: 10.1016/S2665-9913(20)30169-7. [Epub ahead of print]
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;0:1-8.
Gisondi P, Facheris P, Dapavo P, et al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. doi: 10.1111/bjd.19158. [Epub ahead of print]
Haberman R, Axelrad J, Chen R, et al. COVID-19 in immune-mediated inflammatory diseases -- case series from New York. N Engl J Med. 2020;383;1.
Iacucci M, Cannatelli R, Labarile N, et al. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol. 2020;5:598-606.
PsoProtect website. An overview of PsoProtect's current data. Accessed Aug 4, 2020. https://psoprotect.org/current-data/
PsoProtectMe website. An overview of the current data from PsoProtectMe. Accessed Aug 4, 2020. https://psoprotectme.org/current-data/
Rubin DT, Abreu MT, Rai, V, et al. Management of patients with Crohn's disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting. Gastroenterol. 2020. doi: 10.1053/j.gastro.2020.04.002. [Epub ahead of print]
Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Reviews Immunol. 2020;20:271–272.
Simon D, Tascilar K, Kronk G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection. Nat Comm. 2020. doi: 10.1038/s41467-020-17703-6. [Epub ahead of print]
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2021436. [Epub ahead of print].
Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clinical Dermatol. 2020;21:307-311.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Timothy Raine, MD

Gastroenterologist
Addenbrooke's Hospital
Cambridge University Hospitals
Cambridge, UK

Disclosures

Disclosure: Timothy Raine, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Celgene; Ferring; Gilead; GlaxoSmithKline; LabGenius; Janssen Pharmaceutical Companies; Mylan; Merck Sharp & Dohme; Novartis; Pfizer; Sandoz; Takeda; UCB
Received grants for clinical research from: AbbVie

Christopher Griffiths, OBE, MD, FMedSci

Foundation Professor of Dermatology
Consultant Dermatologist Director
University of Manchester
Manchester, UK

Disclosures

Disclosure: Christopher Griffiths, OBE, MD, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Almirall; Celgene; Eli Lilly; Janssen Pharmaceutical Companies; Novartis; Sandoz
Served as a speaker or a member of a speakers bureau for: AbbVie; Almirall; Celgene; Eli Lilly; Janssen Pharmaceutical Companies; Novartis; UCB
Received grants for clinical research from: AbbVie; Celgene; Eli Lilly; Janssen Pharmaceutical Companies; Novartis; UCB

Georg Schett, MD

Chief
Internal Medicine 3
Universitätsklinikum Erlangen
Friedrich-Alexander Universität
Erlangen-Nürnberg, Germany

Disclosures

Disclosure: Prof Georg Schett, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Celgene; Chugai; Eli Lilly; Gilead; Janssen Pharmaceutical Companies; Novartis; Roche; UCB
Served as a speaker or a member of a speakers bureau for: AbbVie; Brisotl Myers Squibb; Celgene; Chugai; Eli Lilly; Gilead; Janssen Pharmaceutical Companies; Novartis; Roche; UCB
Received grants for clinical research from: Bristol Myers Squibb; Celgene; Chugai; Eli Lilly; Novartis; Roche

Editors

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Rosalyn Blumenthal, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Roz Blumenthal, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Anjali Mehra, MD

Lead Medical Education Director

Disclosures

Disclosure: Anjali Mehra, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

What Have We Learned About Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic?

Authors: Tim Raine, MD; Christopher Griffiths, OBE, MD, FMedSci; Georg Schett, MD
CPD Released: 7/30/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 7/30/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US gastroenterologists, dermatologists, and rheumatologists.

The goal of this activity is to increase clinicians' knowledge and competence regarding the management of patients with chronic immune-mediated inflammatory diseases (IMIDs) during the coronavirus disease 2019 (COVID-19) pandemic.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest information on COVID-19 and its impact on patients with inflammatory diseases
- Latest information on safety of continuation of biologic therapies in virus-naive or infected patients
Have greater competence related to
- Managing patients with inflammatory disease who are infected with COVID-19

Disclosures

Faculty

Timothy Raine, MD

Gastroenterologist
Addenbrooke's Hospital
Cambridge University Hospitals
Cambridge, UK

Disclosures

Disclosure: Timothy Raine, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Celgene; Ferring; Gilead; GlaxoSmithKline; LabGenius; Janssen Pharmaceutical Companies; Mylan; Merck Sharp & Dohme; Novartis; Pfizer; Sandoz; Takeda; UCB
Received grants for clinical research from: AbbVie

Christopher Griffiths, OBE, MD, FMedSci

Foundation Professor of Dermatology
Consultant Dermatologist Director
University of Manchester
Manchester, UK

Disclosures

Disclosure: Christopher Griffiths, OBE, MD, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Almirall; Celgene; Eli Lilly; Janssen Pharmaceutical Companies; Novartis; Sandoz
Served as a speaker or a member of a speakers bureau for: AbbVie; Almirall; Celgene; Eli Lilly; Janssen Pharmaceutical Companies; Novartis; UCB
Received grants for clinical research from: AbbVie; Celgene; Eli Lilly; Janssen Pharmaceutical Companies; Novartis; UCB

Georg Schett, MD

Chief
Internal Medicine 3
Universitätsklinikum Erlangen
Friedrich-Alexander Universität
Erlangen-Nürnberg, Germany

Disclosures

Disclosure: Prof Georg Schett, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Celgene; Chugai; Eli Lilly; Gilead; Janssen Pharmaceutical Companies; Novartis; Roche; UCB
Served as a speaker or a member of a speakers bureau for: AbbVie; Brisotl Myers Squibb; Celgene; Chugai; Eli Lilly; Gilead; Janssen Pharmaceutical Companies; Novartis; Roche; UCB
Received grants for clinical research from: Bristol Myers Squibb; Celgene; Chugai; Eli Lilly; Novartis; Roche

Editors

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Rosalyn Blumenthal, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Roz Blumenthal, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Anjali Mehra, MD

Lead Medical Education Director

Disclosures

Disclosure: Anjali Mehra, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

What Have We Learned About Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic?

Authors: Tim Raine, MD; Christopher Griffiths, OBE, MD, FMedSci; Georg Schett, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 7/30/2020

Valid for credit through: 7/30/2021

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available.

Contents of This CPD Activity

All sections of this activity are required for credit.

COVID-19 and Inflammatory Bowel Disease

Dr Raine discusses the impact of COVID-19 on patients with IBD.
Timothy Raine, MD

COVID-19 and Psoriasis

Dr Griffiths discusses the impact of COVID-19 on patients with psoriasis.
Christopher Griffiths, OBE, MD, FMedSci

COVID-19 and Rheumatologic Diseases

Dr Schett concludes with a discussion about the impact of COVID-19 on patients with rheumatic diseases.
Prof Georg Schett, MD

Page 1 of 4

COVID-19 and Inflammatory Bowel Disease

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Timothy Raine, MD

Christopher Griffiths, OBE, MD, FMedSci

Georg Schett, MD

Editors

Roderick Smith, MS

Rosalyn Blumenthal, PhD

Content Reviewer

Anjali Mehra, MD

Peer Reviewer

CPD

What Have We Learned About Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic?

Target Audience and Goal Statement

Disclosures

Faculty

Timothy Raine, MD

Christopher Griffiths, OBE, MD, FMedSci

Georg Schett, MD

Editors

Roderick Smith, MS

Rosalyn Blumenthal, PhD

Content Reviewer

Anjali Mehra, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

What Have We Learned About Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic?

Contents of This CPD Activity